Stopping Cardiovascular Treatments and Mortality in a MICU

Overview

Cardiovascular treatments should not be interrupted following hospital admission, in order to decrease patients' morbidity. However, following ICU admission, such treatments are frequently interrupted and/or modified. The question of the study is to investigate wether such treatment interruption might be responsible for prognosis modifications.

Full Title of Study: “Impact on Mortality of Cardiovascular Treatments Interruption in a Medical Intensive Care Unit”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: November 2, 2019

Detailed Description

Cardiovascular treatments should not be interrupted following hospital admission, in order to decrease patients' morbidity. However, following ICU admission, such treatments are frequently interrupted and/or modified.

Few studies have investigated the outcome impact of medications interruption and/or modifications following hospital admission. We did consider that it might be interesting to study whether treatment continuation, interruption, and/or re-introduction following ICU admission may modify patients' outcome either in the ICU or following hospital discharge (at 3,6 and 12 months).

Interventions

  • Other: Observation
    • No intervention will be performed

Clinical Trial Outcome Measures

Primary Measures

  • ICU Mortality
    • Time Frame: 2 months following ICU Discharge
    • Patients mortality will be assessed at the end of the ICU stay (two months)

Secondary Measures

  • Hospital mortality
    • Time Frame: 2 months following Hospital Discharge
    • Patients mortality will be assessed at the end of the hospitalisation stay (two months)
  • Mortality at Month 3 following discharge
    • Time Frame: 3-months following discharge
  • Mortality at Month 6 following discharge
    • Time Frame: 6-months following discharge
  • Mortality at Month 12 (1-year) following discharge
    • Time Frame: 12-months following discharge

Participating in This Clinical Trial

Inclusion Criteria

  • All patients with cardiovascular treatment prior to ICU admission

Exclusion Criteria

  • Data unavailability
  • Consent withdrawal following information

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Brest
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Erwan L’HERr, +33298347181, erwan.lher@chu-brest.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.